Synthesis and some Pharmacological Properties of an Immunoactive Lysine-Containing Tetrapeptide
- 作者: Kholnazarov B.M.1, Bobizoda G.M.2, Olefir Y.V.1, Prokof’ev A.B.3,1, Sapovskii M.M.3, Evteev V.A.1, Bunyatyan N.D.3,1
- 
							隶属关系: 
							- Scientific Center for Expertise in Medicines, Russian Ministry of Health
- S. Aini Tajik State Pedagogical University
- I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University)
 
- 期: 卷 52, 编号 7 (2018)
- 页面: 611-614
- 栏目: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245368
- DOI: https://doi.org/10.1007/s11094-018-1869-3
- ID: 245368
如何引用文章
详细
The potentially immunoactive lysine-containing tetrapeptide H-Lys-Ala-Val-Gly-OH was synthesized. The value of using a method based on mixed anhydrides and activated esters to obtain tetrapeptide at high yield was demonstrated. The peptide preparation method was improved by replacing p-nitrophenyl esters at the intermediate stage with N-hydroxysuccinimide esters, yielding a crystalline substance at high purity, and replacing the BOC (tert-butyloxycarbonyl) group for protection with a carbobenzoxy group, which provided for a one-step removal of the protection of both amino groups in mild conditions. Comparative assessment of the immunological activity of the tetrapeptide on the background of immunization with sheep erythrocytes in mice with other lysine-containing tetrapeptides showed it to have more marked immunostimulatory activity. Studies of acute and chronic toxicity demonstrated the absence of toxic activity in the lysine-containing tetrapeptide studied here on s.c. administration to experimental animals. The tetrapeptide corresponded to toxicity class 5, i.e., it was essentially nontoxic.
作者简介
B. Kholnazarov
Scientific Center for Expertise in Medicines, Russian Ministry of Health
														Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow						
G. Bobizoda
S. Aini Tajik State Pedagogical University
														Email: ndbun@mail.ru
				                					                																			                												                	塔吉克斯坦, 							Dushanbe						
Yu. Olefir
Scientific Center for Expertise in Medicines, Russian Ministry of Health
														Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow						
A. Prokof’ev
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health
														Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow; Moscow						
M. Sapovskii
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University)
														Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow						
V. Evteev
Scientific Center for Expertise in Medicines, Russian Ministry of Health
														Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow						
N. Bunyatyan
I. M. Sechenov First Moscow State Medical Institute, Russian Ministry of Health (Sechenov University); Scientific Center for Expertise in Medicines, Russian Ministry of Health
							编辑信件的主要联系方式.
							Email: ndbun@mail.ru
				                					                																			                												                	俄罗斯联邦, 							Moscow; Moscow						
补充文件
 
				
			 
						 
						 
					 
						 
						 
				 
  
  
  
  
  电邮这篇文章
			电邮这篇文章  开放存取
		                                开放存取 ##reader.subscriptionAccessGranted##
						##reader.subscriptionAccessGranted## 订阅存取
		                                		                                        订阅存取
		                                					